After scanning all the OTCQB stocks, There is no d
Post# of 416
(Total Views: 376)
Posted On: 06/18/2017 11:01:57 AM
After scanning all the OTCQB stocks, There is no doubt that ENDV's stock has more potential than other OTC stock.
Knowing Biologics spending in Big Pharma will reach 1/3 of all spending in Biotech a lofty 390 Billion Dollars in the next few years. ENDV has a cutting edge platform for Biologics.
ENDV also has a cutting edge Bio Electronic Medicine Platform. Tesla, Google, Apple, GSK, Medtronic, GE, Robert Duggan (PCYC) a majority investor in PLSE 485 Million Market cap. ENDV competitor (14 Million Market cap)
ENDV has 21 Patents for non invasive platform. The insider Buying for ENDV has been consistent and shows confidence among insiders. Two insiders own well over 20 Million shares each. 153 Buys on the open market the last 6 months 0 Sells.
Endonovo's Immunotronics™ platform(Bio Electronic Medicine) is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo's Cytotronics™ platform (Biologics) provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies.
http://analysis.secfilings.com/articles/74-en...erapeutics
http://analysis.secfilings.com/articles/85-th...oceuticals
http://microcapspeculators.com/news/small-bio...cine-race/
http://ir.endonovo.com/press-releases/detail/...n-invasive
http://ir.endonovo.com/press-releases/detail/...ication-on
http://ir.endonovo.com/press-releases/detail/...ion-market
http://endonovo.com/
https://twitter.com/endonovo
$ENDV
Knowing Biologics spending in Big Pharma will reach 1/3 of all spending in Biotech a lofty 390 Billion Dollars in the next few years. ENDV has a cutting edge platform for Biologics.
ENDV also has a cutting edge Bio Electronic Medicine Platform. Tesla, Google, Apple, GSK, Medtronic, GE, Robert Duggan (PCYC) a majority investor in PLSE 485 Million Market cap. ENDV competitor (14 Million Market cap)
ENDV has 21 Patents for non invasive platform. The insider Buying for ENDV has been consistent and shows confidence among insiders. Two insiders own well over 20 Million shares each. 153 Buys on the open market the last 6 months 0 Sells.
Endonovo's Immunotronics™ platform(Bio Electronic Medicine) is a non-invasive, non-implantable bioelectronic device for treating/preventing vital organ failure through the reduction of inflammation and necrosis, and the promotion of regeneration. Endonovo's Cytotronics™ platform (Biologics) provides for a method of expanding and manipulating cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for tissue engineering and cell therapies.
http://analysis.secfilings.com/articles/74-en...erapeutics
http://analysis.secfilings.com/articles/85-th...oceuticals
http://microcapspeculators.com/news/small-bio...cine-race/
http://ir.endonovo.com/press-releases/detail/...n-invasive
http://ir.endonovo.com/press-releases/detail/...ication-on
http://ir.endonovo.com/press-releases/detail/...ion-market
http://endonovo.com/
https://twitter.com/endonovo
$ENDV
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
WORDS TO LIVE BY:
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.
Scroll down for more posts ▼